Consensus statement: summary of the Quebec Lung Cancer Network recommendations for prioritizing patients with thoracic cancers in the context of the COVID-19 pandemic

Curr Oncol. 2020 Jun;27(3):e313-e317. doi: 10.3747/co.27.6685. Epub 2020 Jun 1.

Abstract

Background: The emergence of covid-19 has the potential to change the way in which the health care system can accommodate various patient populations and might affect patients with non-covid-19 problems. The Quebec Lung Cancer Network, which oversees thoracic oncology services in the province of Quebec under the direction of the Ministère de la Santé et des Services sociaux, convened to develop recommendations to deal with the potential disruption of services in thoracic oncology in the province of Quebec. The summary provided here has been adapted from the original document posted on the Programme québécois du cancer Web site at: https://www.msss.gouv.qc.ca/professionnels/documents/coronavirus-2019-ncov/PJ1_Recommandations_oncologie-thoracique-200415.pdf.

Methods: Plans to optimize the health care system and potentially to prioritize services were discussed with respect to various levels of activity. For each level-of-activity scenario, suggestions were made for the services and treatments to prioritize and for those that might have to be postponed, as well as for potential alternatives to care.

Results: The principal recommendation is that the cancer centre executive committee and the multidisciplinary tumour board always try to find a solution to maintain standard-of-care therapy for all patients with thoracic tumours, using novel approaches to treatment and the adoption of a network approach to care, as needed.

Conclusions: The effect of the covid-19 pandemic on the health care system remains unpredictable and requires that cancer teams unite and offer the most efficient and innovative therapies to all patients under the various conditions that might be forced upon them.

Keywords: Thoracic cancer; covid-19; priorities.

Publication types

  • Consensus Development Conference

MeSH terms

  • Administration, Oral
  • Antineoplastic Agents / administration & dosage*
  • Antineoplastic Agents / therapeutic use
  • Betacoronavirus
  • COVID-19
  • Carcinoma, Non-Small-Cell Lung / diagnosis
  • Carcinoma, Non-Small-Cell Lung / therapy*
  • Coronavirus Infections / epidemiology*
  • Disease Management
  • Humans
  • Lung Neoplasms / diagnosis
  • Lung Neoplasms / therapy*
  • Mediastinoscopy
  • Medical Oncology
  • Molecular Diagnostic Techniques
  • Neoplasm Staging
  • Pandemics
  • Pneumonia, Viral / epidemiology*
  • Quebec / epidemiology
  • Radiosurgery
  • Radiotherapy*
  • SARS-CoV-2
  • Small Cell Lung Carcinoma / diagnosis
  • Small Cell Lung Carcinoma / therapy*
  • Thoracic Surgical Procedures*
  • Thoracoscopy
  • Triage*

Substances

  • Antineoplastic Agents